公开(公告)号：US12128062B2

公开(公告)日：2024-10-29

申请号：US17258544

申请日：2019-08-14

Applicant: Ohannes Kevork Melemedjian

Inventor： Ohannes Kevork Melemedjian

IPC: C12N15/11 ,  A61K31/16 ,  A61K31/19 ,  A61K31/7004 ,  A61K31/7105 ,  A61K47/54 ,  C12N15/113

CPC classification number: A61K31/7105 ,  A61K31/16 ,  A61K31/19 ,  A61K31/7004 ,  A61K47/543 ,  A61K47/549 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/346

Abstract: Methods of alleviating or prophylactically blocking pain through the alteration of certain metabolic pathways in a subject experiencing pain or expecting to experience pain are disclosed. In particular, methods of increasing the amount of the neutral amino acid transporter ASCT2 in neurons are disclosed. Increased glutamine uptake by neurons leads to reduced extrusion of lactate and protons into the extracellular space and by extension, reduced sensitization of the neurons. Reduced sensitization of the neurons lessens the feeling of pain in the subject.

公开(公告)号：US12128061B2

公开(公告)日：2024-10-29

申请号：US16147844

申请日：2018-09-30

Applicant: Vycellix, Inc.

Inventor： Evren Alici

IPC: A61K31/7105 ,  A61K9/127 ,  A61K31/7115 ,  A61K38/20 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N15/117

CPC classification number: A61K31/7105 ,  A61K9/1271 ,  A61K31/7115 ,  A61K38/2013 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2320/32 ,  A61K31/7115 ,  A61K2300/00

Abstract: The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.

公开(公告)号：US12122848B2

公开(公告)日：2024-10-22

申请号：US17365723

申请日：2021-07-01

Applicant: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

Inventor： Omid Khorram ,  Tsai-Der Chuang

IPC: C07K16/40 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/7105 ,  A61P15/00 ,  A61P19/04

CPC classification number: C07K16/40 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/7105 ,  A61P15/00 ,  A61P19/04

Abstract: The present disclosure relates generally to compositions and methods for treating fibroid in a patient in need thereof, which entails administering to the patient an effective amount of an agent that inhibits the expression or activity of TDO2 or IDO1.

公开(公告)号：US20240342207A1

公开(公告)日：2024-10-17

申请号：US18294680

申请日：2022-08-02

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Liuqing YANG ,  Chunru LIN ,  Sergey D. EGRANOV ,  Yajuan LI

IPC: A61K31/7105 ,  A61K48/00 ,  A61P3/00 ,  C12N15/11

CPC classification number: A61K31/7105 ,  A61K48/0075 ,  A61P3/00 ,  C12N15/11 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/3517

Abstract: This disclosure provides modified nucleic acids and compositions thereof that are able to mimic the human HULC lncRNA and/or the mouse Pair lncRNA and enhance phenylalanine hydroxylase enzyme (PAH)-substrate binding affinity, PAH-cofactor binding affinity, and/or PAH enzymatic conversion of phenylalanine to tyrosine. Also provided are methods of using the modified nucleic acids and compositions thereof to treat subjects having or suspected of having phenylketonuria and hyperphenylalaninemia.

公开(公告)号：US12116574B2

公开(公告)日：2024-10-15

申请号：US17474949

申请日：2021-09-14

Applicant: Northwestern University

Inventor： William A. Muller ,  Bita F. Cyrus

IPC: C12N15/113 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/00 ,  A61K38/46 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/005 ,  A61K38/46 ,  A61K45/06 ,  C12Y306/04004 ,  C12Y306/04005 ,  C12N2310/14 ,  C12N2310/531 ,  A61K31/713 ,  A61K2300/00 ,  A61K31/7105 ,  A61K2300/00

Abstract: Provided herein are compositions and methods for the inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of inflammation therewith.

公开(公告)号：US12115230B2

公开(公告)日：2024-10-15

申请号：US17918092

申请日：2021-04-09

Applicant: Verve Therapautics, Inc.

Inventor： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC: C12N15/11 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/46 ,  A61K48/00 ,  C07K14/515 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

CPC classification number: A61K48/0066 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/465 ,  C07K14/515 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/331 ,  C12N2310/335 ,  C12N2310/344 ,  C12N2310/3521 ,  C12N2800/80

Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

公开(公告)号：US20240327838A1

公开(公告)日：2024-10-03

申请号：US18492683

申请日：2023-10-23

Applicant: IONIS PHARMACEUTICALS, INC.

Inventor： Jeffrey R. Crosby ,  Shuling Guo ,  Huynh-Hoa Bui ,  Andrew T. Watt ,  Susan M. Freier

IPC: C12N15/113 ,  A61K9/00 ,  A61K31/404 ,  A61K31/47 ,  A61K31/7105 ,  A61K31/713 ,  A61M11/00 ,  A61P11/00

CPC classification number: C12N15/113 ,  A61K9/0019 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/404 ,  A61K31/47 ,  A61K31/7105 ,  A61K31/713 ,  A61P11/00 ,  A61M11/005 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/346 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2320/35

Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.

公开(公告)号：US20240325568A1

公开(公告)日：2024-10-03

申请号：US18580716

申请日：2022-07-20

Applicant: The Broad Institute, Inc.

Inventor： Benjamin Deverman ,  Qin Huang ,  Ken Chan

IPC: A61K48/00 ,  A61K31/7105 ,  A61K38/46 ,  A61K47/64 ,  C12N15/86

CPC classification number: A61K48/0033 ,  A61K31/7105 ,  A61K38/465 ,  A61K47/64 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14145

Abstract: Highly selective targeting moieties and compositions comprising the targeting moieties are described herein to efficiently transduce endothelial cell of the central nervous system vasculature. Embodiments include use and delivery of the targeting moieties and compositions to selectively direct delivery of cargo.

公开(公告)号：US20240325308A1

公开(公告)日：2024-10-03

申请号：US18293419

申请日：2022-08-03

Applicant: The Trustees of the University of Pennsylvania ,  The Children's Hospital of Philadelphia

Inventor： Michael Mitchell ,  Kelsey L. Swingle ,  Margaret M. Billingsley ,  William Peranteau

IPC: A61K9/127 ,  A61K31/7105 ,  G01N33/50

CPC classification number: A61K9/1271 ,  A61K31/7105 ,  G01N33/5026 ,  G01N33/5076

Abstract: The present disclosure relates, in part, to lipid nanoparticles (LNPs), and compositions comprising the same, which have increased stability in amniotic fluid, and methods of use thereof for in utero delivery of therapeutic agents, to treat and/or prevent diseases and/or disorders in a fetal subject. The present disclosure further relates to an ex vivo assay for screening LNP stability in a test fluid.

公开(公告)号：US12102649B2

公开(公告)日：2024-10-01

申请号：US17769986

申请日：2020-10-22

Applicant: AIM ImmunoTech Inc.

Inventor： Thomas K. Equels ,  David R. Strayer

IPC: A61K31/7105 ,  A61K9/00 ,  A61K31/713 ,  A61K35/17 ,  A61P15/00

CPC classification number: A61K31/7105 ,  A61K9/0024 ,  A61K35/17 ,  A61P15/00 ,  A61K31/713

Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).